Table 1.
Patient characteristics
| Variable | 3–6-Month studies | ≥6-Month exposure | 1-Year study | ||
|---|---|---|---|---|---|
| Placebo (N = 535) | Duloxetine (N = 876) | pa (duloxetine vs. placebo) | Duloxetine (N = 721) | Duloxetine (N = 350) | |
| Ethnicity, n (%) | 0.916 | ||||
| African | 13 (2.4%) | 20 (2.3%) | 5 (0.7) | 3 (0.9) | |
| Caucasian | 463 (86.5%) | 771 (88.0%) | 560 (77.7) | 214 (61.1) | |
| East Asian | 3 (0.6%) | 3 (0.3%) | 33 (4.6) | 46 (13.1) | |
| Hispanic | 51 (9.5%) | 76 (8.7%) | 116 (16.1) | 82 (23.4) | |
| Nat. Amer. | 1 (0.2%) | 2 (0.2%) | 4 (0.6) | 1 (0.3) | |
| Other | 3 (0.6%) | 2 (0.2%) | – | – | |
| West Asian | 1 (0.2%) | 2 (0.2%) | 3 (0.4) | 4 (1.1) | |
| Age, yearsb | 49.61 (11.32) | 50.62 (10.76) | 0.147 | 50.48 (10.56) | 48.97 (11.07) |
| Gender, n (%) | 0.265 | ||||
| Female | 509 (95.1%) | 829 (94.6%) | 692 (96.0) | 335 (95.7) | |
| Height (cm)2 | 163.14 (7.49) | 163.32 (7.78) | 0.512 | 161.76 (7.47) | 159.44 (7.09) |
| Weight (kg)2 | 78.15 (18.40) | 79.71 (19.46) | 0.582 | 76.84 (18.37) | 69.95 (14.74) |
aFrequencies were analyzed using Cochran–Mantel–Haenszel test for general association controlling for study; means were analyzed using a type III sums of squares analysis of variance: model = treatment and study
bMean (SD)